Rationale: Regular cannabis use has been associated with brain functional alterations within frontal, temporal, and striatal pathways assessed during various cognitive tasks. Whether such alterations are consistently reported in the absence of overt task performance needs to be elucidated to uncover the core neurobiological mechanisms of regular cannabis use.
Objectives: We aim to systematically review findings from studies that examine spontaneous fluctuations of brain function using functional Magnetic Resonance Imaging (fMRI) resting-state functional connectivity (rsFC) in cannabis users versus controls, and the association between rsFC and cannabis use chronicity, mental health symptoms, and cognitive performance.
Methods: We conducted a PROSPERO registered systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and searched eight databases.
Results: Twenty-one studies were included for review. Samples comprised 1396 participants aged 16 to 42 years, of which 737 were cannabis users and 659 were controls. Most studies found greater positive rsFC in cannabis users compared to controls between frontal-frontal, fronto-striatal, and fronto-temporal region pairings. The same region pairings were found to be preliminarily associated with varying measures of cannabis exposure.
Conclusions: The evidence to date shows that regular cannabis exposure is consistently associated with alteration of spontaneous changes in Blood Oxygenation Level-Dependent signal without any explicit cognitive input or output. These findings have implications for interpreting results from task-based fMRI studies of cannabis users, which may additionally tax overlapping networks. Future longitudinal rsFC fMRI studies are required to determine the clinical relevance of the findings and their link to the chronicity of use, mental health, and cognitive performance.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00213-021-05938-0 | DOI Listing |
J Med Internet Res
January 2025
Division of Sleep Medicine, Harvard Medical School, Boston, MA, United States.
Background: People share health-related experiences and treatments, such as for insomnia, in digital communities. Natural language processing tools can be leveraged to understand the terms used in digital spaces to discuss insomnia and insomnia treatments.
Objective: The aim of this study is to summarize and chart trends of insomnia treatment terms on a digital insomnia message board.
Obstet Med
December 2024
Specialist Perinatal Mental Health Service, University Maternity Hospital Limerick, Limerick, Ireland.
Background: Cannabinoid hyperemesis syndrome (CHS) is a syndrome of cyclic nausea and vomiting in the setting of chronic cannabis use. To date, only 11 cases of CHS in pregnancy have been reported.
Case Presentation: We describe two cases of uncontrolled vomiting in pregnancy due to CHS.
Toxicol Rep
December 2024
Division of Health and Applied Sciences, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand.
Warfarin, a commonly prescribed anticoagulant, is utilized to prevent thrombotic issues and requires careful dose adjustment due to its narrow therapeutic range. As warfarin is metabolized by essential drug-metabolizing enzymes (DMEs), it is prone to interactions with a wide range of therapeutic agents, including herbal medicines. In June 2022, Thailand became the first country in Asia to remove cannabis plants from its narcotics control list, allowing individuals to cultivate them for personal use.
View Article and Find Full Text PDFPsychol Med
December 2024
Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
Background: The association between cannabis and psychosis is established, but the role of underlying genetics is unclear. We used data from the EU-GEI case-control study and UK Biobank to examine the independent and combined effect of heavy cannabis use and schizophrenia polygenic risk score (PRS) on risk for psychosis.
Methods: Genome-wide association study summary statistics from the Psychiatric Genomics Consortium and the Genomic Psychiatry Cohort were used to calculate schizophrenia and cannabis use disorder (CUD) PRS for 1098 participants from the EU-GEI study and 143600 from the UK Biobank.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!